Reports
Reports
Sale
The key features of the global cell therapy market report include patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Vericel Corporation
Vericel Corporation is a public, American biopharmaceutical company, with a manufacturing facility in Massachusetts (Cambridge). It develops and markets advanced cell therapies in areas of sports medicine and severe burn care and has a robust presence in the U.S. cell therapy market. The company has a strong product portfolio including autologous cultured chondrocytes on porcine collagen membrane (MACI) to treat cartilage defects and Epicel cultured epidermal autografts for skin replacement. The biopharma company also holds an exclusive license for NexoBrid (anacaulase-bcdb) in North America for treating severe thermal burns.
Kolon TissueGene Inc.
This biotechnology company specializes in the development of cell and gene therapies for the treatment of osteoarthritis and other orthopedic conditions. Its novel cell and gene therapy for knee osteoarthritis, INVOSSA-K, was approved in South Korea in 2017 but was later retracted in 2019. Kolon TissueGene is actively working on the preclinical and clinical development of its pipeline products to expand its cell and gene therapies portfolio for treating various orthopedic and musculoskeletal disorders and is expected to significantly contribute to bringing cell therapy innovations into the market.
JCR Pharmaceuticals Co. Ltd
This Japanese biopharmaceutical company focuses on the development and commercialization of innovative therapies, including cell and gene therapies. Its allogeneic cell therapy JR-031 (Temcell HS Inj.) is a mesenchymal stem cell (MSC) therapy used to treat graft-versus-host disease (GVHD). The company heavily invests in R&D activities and has several cell therapy candidates in various stages of preclinical and clinical development. The pharmaceutical company is also aiming for global commercialization via strategic partnerships with international companies and is likely to elevate the cell therapy market value in the forecast period.
MEDIPOST Co. Ltd.
MEDIPOST Co. Ltd., a South Korean biotechnology company, has a prominent presence in the market. Its allogeneic umbilical cord blood-derived mesenchymal stem cell therapy, Cartistem, is designed for the treatment of knee cartilage defects and osteoarthritis. The company is known to actively collaborate with academic institutions, research organizations, and other biotech companies to advance and expand its cell therapy pipeline.
Other players in the cell therapy market include Osiris (Mesoblast), Stemedica Cell Technologies Inc., ImmunoACT, Castle Creek Biosciences, Inc., PHARMICELL Co. Ltd, ANTEROGEN.CO.LTD, Novartis AG, Celgene Corp. (Bristol-Myers Squibb Company), Allogene Therapeutics Inc., and Stempeutics Research Pvt. Ltd, among others.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell Therapy Market Overview
3.1 Global Cell Therapy Market Historical Value (2017-2023)
3.2 Global Cell Therapy Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Cell Therapy Market Landscape*
5.1 Global Cell Therapy: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Cell Therapy: Product Landscape
5.2.1 Analysis by Type
5.2.2 Analysis by Type of Therapy
5.2.3 Analysis by End User
6 Global Cell Therapy Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Cell Therapy Market Segmentation (2017-2032)
7.1 Global Cell Therapy Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Stem Cell
7.1.2.1 Bone Marrow Derived Mesenchymal Stem Cell
7.1.2.2 Hematopoietic Stem Cells
7.1.2.3 Umbilical Cord Derived Stem Cell
7.1.2.4 Adipose Derived Stem Cell
7.1.2.5 Skin Stem Cells
7.1.2.6 Induced Pluripotent Stem Cells
7.1.2.7 Others
7.1.3 Non-Stem Cell (Dendritic Cell, CART-Cell)
7.2 Global Cell Therapy Market (2017-2032) by Type of Therapy
7.2.1 Market Overview
7.2.2 Autologous
7.2.3 Allogeneic
7.3 Global Cell Therapy Market (2017-2032) by Therapeutic Area
7.3.1 Market Overview
7.3.2 Musculoskeletal Disorders
7.3.3 Cardiovascular Diseases
7.3.4 Neurological Disorders
7.3.5 Oncological Disorders
7.3.6 Dermatology
7.3.7 Inflammatory And Autoimmune Disorders
7.3.8 Others
7.4 Global Cell Therapy Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Hospitals and Clinics
7.4.3 Regenerative Medicine Centers
7.4.4 Diagnostic and Research Centers
7.4.5 Others
7.5 Global Cell Therapy Market (2017-2032) by Region
7.5.1 Market Overview
7.5.2 North America
7.5.3 Europe
7.5.4 Asia Pacific
7.5.5 Latin America
7.5.6 Middle East and Africa
8 North America Cell Therapy Market (2017-2032)
8.1 North America Cell Therapy Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Stem Cell
8.1.2.1 Bone Marrow Derived Mesenchymal Stem Cell
8.1.2.2 Hematopoietic Stem Cells
8.1.2.3 Umbilical Cord Derived Stem Cell
8.1.2.4 Adipose Derived Stem Cell
8.1.2.5 Skin Stem Cells
8.1.2.6 Induced Pluripotent Stem Cells
8.1.2.7 Others
8.1.3 Non-Stem Cell (Dendritic Cell, CART-Cell)
8.2 North America Cell Therapy Market (2017-2032) by Type of Therapy
8.2.1 Market Overview
8.2.2 Autologous
8.2.3 Allogeneic
8.3 North America Cell Therapy Market (2017-2032) by Therapeutic Area
8.3.1 Market Overview
8.3.2 Musculoskeletal Disorders
8.3.3 Cardiovascular Diseases
8.3.4 Neurological Disorders
8.3.5 Oncological Disorders
8.3.6 Dermatology
8.3.7 Inflammatory And Autoimmune Disorders
8.3.8 Others
8.4 North America Cell Therapy Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospitals and Clinics
8.4.3 Regenerative Medicine Centers
8.4.4 Diagnostic and Research Centers
8.4.5 Others
8.5 North America Cell Therapy Market (2017-2032) by Country
8.5.1 United States of America
8.5.2 Canada
9 Europe Cell Therapy Market (2017-2032)
9.1 Europe Cell Therapy Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Stem Cell
9.1.2.1 Bone Marrow Derived Mesenchymal Stem Cell
9.1.2.2 Hematopoietic Stem Cells
9.1.2.3 Umbilical Cord Derived Stem Cell
9.1.2.4 Adipose Derived Stem Cell
9.1.2.5 Skin Stem Cells
9.1.2.6 Induced Pluripotent Stem Cells
9.1.2.7 Others
9.1.3 Non-Stem Cell (Dendritic Cell, CART-Cell)
9.2 Europe Cell Therapy Market (2017-2032) by Type of Therapy
9.2.1 Market Overview
9.2.2 Autologous
9.2.3 Allogeneic
9.3 Europe Cell Therapy Market (2017-2032) by Therapeutic Area
9.3.1 Market Overview
9.3.2 Musculoskeletal Disorders
9.3.3 Cardiovascular Diseases
9.3.4 Neurological Disorders
9.3.5 Oncological Disorders
9.3.6 Dermatology
9.3.7 Inflammatory And Autoimmune Disorders
9.3.8 Others
9.4 Europe Cell Therapy Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Hospitals and Clinics
9.4.3 Regenerative Medicine Centers
9.4.4 Diagnostic and Research Centers
9.4.5 Others
9.5 Europe Cell Therapy Market (2017-2032) by Country
9.5.1 United Kingdom
9.5.2 Germany
9.5.3 France
9.5.4 Italy
9.5.5 Others
10 Asia Pacific Cell Therapy Market (2017-2032)
10.1 Asia Pacific Cell Therapy Market (2017-2032) by Type
10.1.1 Market Overview
10.1.2 Stem Cell
10.1.2.1 Bone Marrow Derived Mesenchymal Stem Cell
10.1.2.2 Hematopoietic Stem Cells
10.1.2.3 Umbilical Cord Derived Stem Cell
10.1.2.4 Adipose Derived Stem Cell
10.1.2.5 Skin Stem Cells
10.1.2.6 Induced Pluripotent Stem Cells
10.1.2.7 Others
10.1.3 Non-Stem Cell (Dendritic Cell, CART-Cell)
10.2 Asia Pacific Cell Therapy Market (2017-2032) by Type of Therapy
10.2.1 Market Overview
10.2.2 Autologous
10.2.3 Allogeneic
10.3 Asia Pacific Cell Therapy Market (2017-2032) by Therapeutic Area
10.3.1 Market Overview
10.3.2 Musculoskeletal Disorders
10.3.3 Cardiovascular Diseases
10.3.4 Neurological Disorders
10.3.5 Oncological Disorders
10.3.6 Dermatology
10.3.7 Inflammatory And Autoimmune Disorders
10.3.8 Others
10.4 Asia Pacific Cell Therapy Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Hospitals and Clinics
10.4.3 Regenerative Medicine Centers
10.4.4 Diagnostic and Research Centers
10.4.5 Others
10.5 Asia Pacific Cell Therapy Market (2017-2032) by Country
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 ASEAN
10.5.5 Australia
10.5.6 Others
11 Latin America Cell Therapy Market (2017-2032)
11.1 Latin America Cell Therapy Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Stem Cell
11.1.2.1 Bone Marrow Derived Mesenchymal Stem Cell
11.1.2.2 Hematopoietic Stem Cells
11.1.2.3 Umbilical Cord Derived Stem Cell
11.1.2.4 Adipose Derived Stem Cell
11.1.2.5 Skin Stem Cells
11.1.2.6 Induced Pluripotent Stem Cells
11.1.2.7 Others
11.1.3 Non-Stem Cell (Dendritic Cell, CART-Cell)
11.2 Latin America Cell Therapy Market (2017-2032) by Type of Therapy
11.2.1 Market Overview
11.2.2 Autologous
11.2.3 Allogeneic
11.3 Latin America Cell Therapy Market (2017-2032) by Therapeutic Area
11.3.1 Market Overview
11.3.2 Musculoskeletal Disorders
11.3.3 Cardiovascular Diseases
11.3.4 Neurological Disorders
11.3.5 Oncological Disorders
11.3.6 Dermatology
11.3.7 Inflammatory And Autoimmune Disorders
11.3.8 Others
11.4 Latin America Cell Therapy Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Hospitals and Clinics
11.4.3 Regenerative Medicine Centers
11.4.4 Diagnostic and Research Centers
11.4.5 Others
11.5 Latin America Cell Therapy Market (2017-2032) by Country
11.5.1 Brazil
11.5.2 Argentina
11.5.3 Mexico
11.5.4 Others
12 Middle East and Africa Cell Therapy Market (2017-2032)
12.1 Middle East and Africa Cell Therapy Market (2017-2032) by Type
12.1.1 Market Overview
12.1.2 Stem Cell
12.1.2.1 Bone Marrow Derived Mesenchymal Stem Cell
12.1.2.2 Hematopoietic Stem Cells
12.1.2.3 Umbilical Cord Derived Stem Cell
12.1.2.4 Adipose Derived Stem Cell
12.1.2.5 Skin Stem Cells
12.1.2.6 Induced Pluripotent Stem Cells
12.1.2.7 Others
12.1.3 Non-Stem Cell (Dendritic Cell, CART-Cell)
12.2 Middle East and Africa Cell Therapy Market (2017-2032) by Type of Therapy
12.2.1 Market Overview
12.2.2 Autologous
12.2.3 Allogeneic
12.3 Middle East and Africa Cell Therapy Market (2017-2032) by Therapeutic Area
12.3.1 Market Overview
12.3.2 Musculoskeletal Disorders
12.3.3 Cardiovascular Diseases
12.3.4 Neurological Disorders
12.3.5 Oncological Disorders
12.3.6 Dermatology
12.3.7 Inflammatory And Autoimmune Disorders
12.3.8 Others
12.4 Middle East and Africa Cell Therapy Market (2017-2032) by End User
12.4.1 Market Overview
12.4.2 Hospitals and Clinics
12.4.3 Regenerative Medicine Centers
12.4.4 Diagnostic and Research Centers
12.4.5 Others
12.5 Middle East and Africa Cell Therapy Market (2017-2032) by Country
12.5.1 Saudi Arabia
12.5.2 United Arab Emirates
12.5.3 Nigeria
12.5.4 South Africa
12.5.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Clinical Trial Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Grant Analysis
16.1 Analysis by Year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Product
16.5 Analysis by Funding Institute
16.6 Analysis by Departments
16.7 Analysis by Recipient Organization
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Type of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Strategic Initiatives
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Partnership
18.3 Analysis by Leading Players
18.4 Analysis by Geography
19 Supplier Landscape
19.1 Market Share Analysis, By Region (Top 5 Companies)
19.1.1 Market Share Analysis: Global
19.1.2 Market Share Analysis: North America
19.1.3 Market Share Analysis: Europe
19.1.4 Market Share Analysis: Asia-Pacific
19.1.5 Market Share Analysis: Others
19.2 Vericel Corporation
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Mergers and Acquisitions
19.2.5 Certifications
19.3 Kolon TissueGene Inc .
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Mergers and Acquisitions
19.3.5 Certifications
19.4 JCR Pharmaceuticals Co. Ltd
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Mergers and Acquisitions
19.4.5 Certifications
19.5 MEDIPOST Co. Ltd .
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Mergers and Acquisitions
19.5.5 Certifications
19.6 Osiris (Mesoblast)
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Mergers and Acquisitions
19.6.5 Certifications
19.7 Stemedica Cell Technologies Inc .
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Mergers and Acquisitions
19.7.5 Certifications
19.8 ImmunoACT
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Mergers and Acquisitions
19.8.5 Certifications
19.9 Castle Creek Biosciences, Inc .
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Mergers and Acquisitions
19.9.5 Certifications
19.10 PHARMICELL Co. Ltd
19.10.1 Financial Analysis
19.10.2 Product Portfolio
19.10.3 Demographic Reach and Achievements
19.10.4 Mergers and Acquisitions
19.10.5 Certifications
19.11 ANTEROGEN.CO.LTD
19.11.1 Financial Analysis
19.11.2 Product Portfolio
19.11.3 Demographic Reach and Achievements
19.11.4 Mergers and Acquisitions
19.11.5 Certifications
19.12 Novartis AG
19.12.1 Financial Analysis
19.12.2 Product Portfolio
19.12.3 Demographic Reach and Achievements
19.12.4 Mergers and Acquisitions
19.12.5 Certifications
19.13 Celgene Corp. (Bristol-Myers Squibb Company)
19.13.1 Financial Analysis
19.13.2 Product Portfolio
19.13.3 Demographic Reach and Achievements
19.13.4 Mergers and Acquisitions
19.13.5 Certifications
19.14 Allogene Therapeutics Inc .
19.14.1 Financial Analysis
19.14.2 Product Portfolio
19.14.3 Demographic Reach and Achievements
19.14.4 Mergers and Acquisitions
19.14.5 Certifications
19.15 Stempeutics Research Pvt. Ltd
19.15.1 Financial Analysis
19.15.2 Product Portfolio
19.15.3 Demographic Reach and Achievements
19.15.4 Mergers and Acquisitions
19.15.5 Certifications
20 Global Cell Therapy Market – Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.